4DMT to Participate in the 2024 Cantor Global Healthcare Conference
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage genetic medicines company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 8:35 a.m. ET. Additionally, they will be available for one-on-one meetings with investors.
A live webcast of the presentation will be accessible, and an archived version will remain available for up to one year on the company's website. This event provides an opportunity for 4DMT to showcase its progress in developing genetic medicines for large market diseases and engage with the investment community.
4D Molecular Therapeutics (Nasdaq: FDMT), un'azienda farmaceutica di tipo genetico in fase clinica, ha annunciato la sua partecipazione alla 2024 Cantor Global Healthcare Conference. La direzione dell'azienda parteciperà a una chat informale giovedì 19 settembre 2024, alle 8:35 ET. Inoltre, saranno disponibili per incontri individuali con gli investitori.
Una trasmissione in diretta della presentazione sarà accessibile e una versione archiviata rimarrà disponibile per un anno sul sito web dell'azienda. Questo evento offre a 4DMT l'opportunità di mostrare i suoi progressi nello sviluppo di medicinali genetici per malattie di grande mercato e di interagire con la comunità degli investitori.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa de medicamentos genéticos en fase clínica, ha anunciado su participación en la 2024 Cantor Global Healthcare Conference. La dirección de la empresa participará en una charla informal el jueves 19 de septiembre de 2024, a las 8:35 a.m. ET. Además, estarán disponibles para reuniones individuales con inversores.
Se podrá acceder a una transmisión en vivo de la presentación, y una versión archivada permanecerá disponible durante un año en el sitio web de la empresa. Este evento proporciona a 4DMT la oportunidad de mostrar su progreso en el desarrollo de medicamentos genéticos para enfermedades de gran mercado e interactuar con la comunidad de inversores.
4D Molecular Therapeutics (Nasdaq: FDMT), 임상 단계의 유전자 의학 회사, 가 2024 Cantor Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 19일 목요일, 오전 8:35 ET에 파이어사이드 채팅에 참여할 예정입니다. 또한 투자자와의 일대일 미팅에 참석할 수 있습니다.
프레젠테이션의 실시간 웹 방송이 제공될 예정이며, 아카이브된 버전은 회사 웹사이트에서 최대 1년 동안 사용할 수 있습니다. 이 이벤트는 4DMT가 대규모 시장 질환을 위한 유전자 의약품 개발의 진행 상황을 보여주고 투자 커뮤니티와 교류할 수 있는 기회를 제공합니다.
4D Molecular Therapeutics (Nasdaq: FDMT), une entreprise de médicaments génétiques en phase clinique, a annoncé sa participation à la 2024 Cantor Global Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le jeudi 19 septembre 2024, à 8h35 ET. De plus, ils seront disponibles pour des réunions individuelles avec des investisseurs.
Une diffusion en direct de la présentation sera accessible, et une version archivée restera disponible pendant un an sur le site web de l'entreprise. Cet événement offre à 4DMT l'opportunité de mettre en avant ses progrès dans le développement de médicaments génétiques pour des maladies de grande envergure et d'interagir avec la communauté des investisseurs.
4D Molecular Therapeutics (Nasdaq: FDMT), ein Unternehmen für genetische Medikamente in der klinischen Phase, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Donnerstag, den 19. September 2024, um 8:35 Uhr ET an einem Kamin-Gespräch teilnehmen. Darüber hinaus stehen sie für persönliche Gespräche mit Investoren zur Verfügung.
Eine Live-Übertragung der Präsentation wird zugänglich sein, und eine archivierte Version wird bis zu einem Jahr auf der Unternehmenswebsite verfügbar bleiben. Diese Veranstaltung bietet 4DMT die Möglichkeit, seine Fortschritte bei der Entwicklung genetischer Medikamente für große Marktkrankheiten zu präsentieren und mit der Investmentgemeinschaft in Kontakt zu treten.
- None.
- None.
EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. Members of the management team will also be available for one-on-one meetings.
2024 Cantor Global Healthcare Conference
| Presentation Date: | Thursday, September 19, 2024 |
| Presentation Time: | 8:35 a.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine helps us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing six clinical-stage and one preclinical product candidate, each tailored to address rare and large market diseases in ophthalmology, pulmonology and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine Smith
Inizio Evoke Comms
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the 2024 Cantor Global Healthcare Conference?
Will there be a webcast of FDMT's presentation at the Cantor Global Healthcare Conference?
What type of engagement will FDMT have at the 2024 Cantor Global Healthcare Conference?
Where can investors find the webcast of FDMT's presentation at the Cantor conference?
